Association between TGFB1 915G/C polymorphism and susceptibility to chronic hepatitis C virus infection: A meta‑analysis

Hu,Guo‑Rui; Zheng,Bi‑Xia; Liu,Zhi‑Feng

doi:10.3892/br.2014.230

Association between TGFB1 915G/C polymorphism and susceptibility to chronic hepatitis C virus infection: A meta‑analysis

Authors:
- Guo‑Rui Hu
- Bi‑Xia Zheng
- Zhi‑Feng Liu
View Affiliations

Affiliations: Medical College of Nanjing University, Nanjing, Jiangsu 210093, P.R. China, Department of Digestive Disease, Nanjing Children's Hospital, Nanjing Medical University, Nanjing, Jiangsu 210008, P.R. China
Published online on: January 24, 2014 https://doi.org/10.3892/br.2014.230
Pages: 239-244

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The human transforming growth factor‑β1 (TGF‑β1) gene, namely TGFB1, contains several single‑nucleotide polymorphisms (SNPs) and some of the polymorphic variants were shown to affect the TGF‑β1 protein levels. A number of studies reported the association between 915G/C polymorphism and susceptibility to chronic hepatitis C virus (HCV) infection. However, the results were inconsistent. This meta‑analysis was conducted to assess the association of TGFB1 915G̸C polymorphism with susceptibility to chronic HCV infection. PubMed, ISI Web of Knowledge, ScienceDirect and Google Scholar databases were systematically searched up to August, 2013 to identify relevant studies. The pooled odds ratios (ORs) with their corresponding 95% confidence intervals (95% CIs) were calculated in 5 genetic comparison models (C vs. G, CC vs. GG, GC vs. GG, CC vs. GG+GC and CC+GC vs. GG). The Galbraith plot and subgroup analyses based on ethnicity, genotyping methods, sample size and fibrosis were performed to investigate possible sources of heterogeneity. A sensitivity analysis and assessment of publication bias were also conducted. Finally, 8 eligible case‑control studies on TGFB1 915G/C polymorphism, including a total of 910 cases and 632 controls, were included in this meta‑analysis. Overall, there was no evidence of any gene‑disease association obtained from the subgroup analyses. Therefore, this meta‑analysis demonstrated that there is no association between TGFB1 915G/C polymorphisms and susceptibility to chronic HCV infection.

View Figures

View References

1	Lavanchy D: The global burden of hepatitis C. Liver Int. 29(Suppl 1): 74–81. 2009. View Article : Google Scholar
2	Lauer GM and Walker BD: Hepatitis C virus infection. N Engl J Med. 345:41–52. 2001. View Article : Google Scholar : PubMed/NCBI
3	Boyer N and Marcellin P: Pathogenesis, diagnosis and management of hepatitis C. J Hepatol. 32(Suppl 1): 98–112. 2000. View Article : Google Scholar
4	Clarke DC and Liu X: Decoding the quantitative nature of TGF-beta/Smad signaling. Trends Cell Biol. 18:430–442. 2008. View Article : Google Scholar : PubMed/NCBI
5	Li MO, Sanjabi S and Flavell RA: Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 25:455–471. 2006. View Article : Google Scholar : PubMed/NCBI
6	Nelson DR, Gonzalez-Peralta RP, Qian K, et al: Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepat. 4:29–35. 1997. View Article : Google Scholar : PubMed/NCBI
7	de Andrade DR Jr and de Andrade DR: The influence of the human genome on chronic viral hepatitis outcome. Rev Inst Med Trop Sao Paulo. 46:119–126. 2004.PubMed/NCBI
8	Tsushima H, Kawata S, Tamura S, et al: Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J Hepatol. 30:1–7. 1999. View Article : Google Scholar
9	Kondo Y, Ueno Y and Shimosegawa T: Dysfunction of immune systems and host genetic factors in hepatitis C virus infection with persistent normal ALT. Hepat Res Treat. 2011:7132162011.PubMed/NCBI
10	Fujii D, Brissenden JE, Derynck R and Francke U: Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet. 12:281–288. 1986. View Article : Google Scholar : PubMed/NCBI
11	Grainger DJ, Heathcote K, Chiano M, et al: Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 8:93–97. 1999. View Article : Google Scholar : PubMed/NCBI
12	Ben-Ari Z, Pappo O, Druzd T, et al: Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine. 27:7–14. 2004. View Article : Google Scholar : PubMed/NCBI
13	Falleti E, Fabris C, Toniutto P, et al: TGF-beta1 genotypes in cirrhosis: relationship with the occurrence of liver cancer. Cytokine. 44:256–261. 2008. View Article : Google Scholar : PubMed/NCBI
14	Vidigal PG, Germer JJ and Zein NN: Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol. 36:271–277. 2002. View Article : Google Scholar : PubMed/NCBI
15	Romani S, Azimzadeh P, Mohebbi SR, et al: Investigation of transforming growth factor-beta1 gene polymorphisms among Iranian patients with chronic hepatitis C. Hepat Mon. 11:901–906. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pereira FA, Pinheiro da Silva NN, Rodart IF, Carmo TM, Lemaire DC and Reis MG: Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol. 80:58–64. 2008. View Article : Google Scholar : PubMed/NCBI
17	Fang J, Liu ZW and Han QY: Polymorphism of codon25 in signal peptide region of transforming growth factor beta 1 and its association with chronic hepatitis C virus infection. Chin J Hepatol. 6:586–589. 2008.(In Chinese).
18	Armendariz-Borunda J, Rincon AR, Munoz-Valle JF, et al: Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. J Investig Med. 56:944–953. 2008.
19	Wang H, Mengsteab S, Tag CG, et al: Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol. 11:1929–1936. 2005. View Article : Google Scholar : PubMed/NCBI
20	Zein NN, Germer JJ, El-Zayadi AR and Vidigal PG: Ethnic differences in polymorphisms of tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in patients with chronic hepatitis C virus infection. Am J Trop Med Hyg. 70:434–437. 2004.PubMed/NCBI
21	Suzuki S, Tanaka Y, Orito E, et al: Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 18:1139–1143. 2003. View Article : Google Scholar : PubMed/NCBI
22	Thakkinstian A, McElduff P, D’Este C, Duffy D and Attia J: A method for meta-analysis of molecular association studies. Stat Med. 24:1291–1306. 2005. View Article : Google Scholar : PubMed/NCBI
23	Attia J, Thakkinstian A and D’Este C: Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 56:297–303. 2003. View Article : Google Scholar : PubMed/NCBI
24	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
25	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
26	Paul SR and Donner A: Small sample performance of tests of homogeneity of odds ratios in K 2×2 tables. Stat Med. 11:159–165. 1992.PubMed/NCBI
27	Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002. View Article : Google Scholar : PubMed/NCBI
28	Bax L, Ikeda N, Fukui N, Yaju Y, Tsuruta H and Moons KG: More than numbers: the power of graphs in meta-analysis. Am J Epidemiol. 169:249–255. 2009. View Article : Google Scholar : PubMed/NCBI
29	Ascione A, Tartaglione T and Di Costanzo GG: Natural history of chronic hepatitis C virus infection. Dig Liver Dis. 39(Suppl 1): S4–S7. 2007. View Article : Google Scholar
30	Roffi L, Ricci A, Ogliari C, et al: HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol. 29:701–706. 1998. View Article : Google Scholar : PubMed/NCBI
31	Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B and Roth WK: Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology. 24:1003–1009. 1996. View Article : Google Scholar : PubMed/NCBI
32	Bortolotti F, Resti M, Marcellini M, et al: Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome. Gut. 54:852–857. 2005. View Article : Google Scholar : PubMed/NCBI
33	Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP and Wedemeyer H: High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 73:387–391. 2004. View Article : Google Scholar : PubMed/NCBI
34	Bellanti F, Vendemiale G, Altomare E and Serviddio G: The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Dev Immunol. 2012:8493732012. View Article : Google Scholar : PubMed/NCBI
35	Birerdinc A, Afendy A, Stepanova M, Younossi I, Baranova A and Younossi ZM: Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). Brain Behav. 2:525–531. 2012. View Article : Google Scholar : PubMed/NCBI
36	Hall CH, Kassel R, Tacke RS and Hahn YS: HCV⁺hepatocytes induce human regulatory CD4⁺T cells through the production of TGF-beta. PloS One. 5:e121542010.PubMed/NCBI
37	Dooley S and ten Dijke P: TGF-beta in progression of liver disease. Cell Tissue Res. 347:245–256. 2012. View Article : Google Scholar : PubMed/NCBI
38	Presser LD, Haskett A and Waris G: Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-beta1: role of TGF-beta1 in HCV replication. Virology. 412:284–296. 2011. View Article : Google Scholar : PubMed/NCBI
39	Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ and Hutchinson IV: Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 66:1014–1020. 1998.PubMed/NCBI
40	Presser LD, McRae S and Waris G: Activation of TGF-beta1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-beta1 in hepatic stellate cell activation and invasion. PloS One. 8:e563672013. View Article : Google Scholar : PubMed/NCBI
41	Mehmedovic A, Mesihovic R, Prnjavorac B, et al: Non-invasive liver fibrosis markers: use of serum levels of cytokines IL 1α and TGF β1 in management of chronic liver diseases. Med Glas (Zenica). 10:20–27. 2013.PubMed/NCBI
42	Powell EE, Edwards-Smith CJ, Hay JL, et al: Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 31:828–833. 2000. View Article : Google Scholar : PubMed/NCBI